
Sensible Biotechnologies
Advancing Naturally Modified mRNA Platform to unlock next generation of mRNA medicines
About
Advancing Naturally Modified mRNA Platform to unlock next generation of mRNA medicines. Sensible Biotechnologies is advancing a Naturally Modified mRNA Platform to unlock next generation of mRNA medicines.
Key facts
At-a-glance profile data
- Website
- sensible.bio
- Headquarters
- Oxford, England, United Kingdom
- Total funding
- $47M (Funding Round)
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 6 Oct 2026 | Funding Round | $47M | - |
Tech stack
Detected on sensible.bio, last scanned 19 Oct 2026. Run your own scan
- CMS / Builders
- Webflow
- CDN
- Cloudflare
- Email provider
- Google Workspace
- Maps
- Mapbox
- Integration capability
- Linear, Webflow
“Sensible Biotechnologies Announces Partnership with Ginkgo Bioworks to Develop Novel mRNA Manufacturing Platform - DNA DNA.WS.”
View on RedditSome comments are pulled from public discussions around the web (look for the source icon). Quotes are excerpts; click through to read the full thread.
Frequently asked
What is Sensible Biotechnologies's Effective Domain Rating?
StartupHub's Effective Domain Rating for Sensible Biotechnologies is 47 out of 100, measuring real cross-surface visibility in search engines and AI answers rather than claimed link authority. That is underrated against its Ahrefs Domain Rating of 32, meaning it surfaces in search and AI results more than its claimed authority alone would suggest.
Is Sensible Biotechnologies trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Sensible Biotechnologies is 68 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Sensible Biotechnologies raised?
Sensible Biotechnologies has raised a total of $47M in funding. The most recent round on record is Funding Round.
